Skip to main content

$0.010 (0%)

High

$0.01

Low

$0.01

Trades

20

Turnover

$16,459

Volume

1,641,703
30 June 2023 at 4:10pm
Register to track PAB and receive email alerts.
PAB Announcements on Price Chart

Latest Announcements

Headline Date
PAT-DX1 GLP toxicology reports received 24 May 2023 at 9:35am
Notification regarding unquoted securities - PAB 11 May 2023 at 2:25pm
Appendix 4C - Quarterly - 31 March 2023 24 April 2023 at 10:35am
Notification of cessation of securities - PAB 18 April 2023 at 4:50pm
Two new deoxymab patents granted in the USA 17 April 2023 at 9:50am
Updated guidance for PAT-DX1 phase 1 clinical study 31 March 2023 at 9:30am
New PAT-DX3 data demonstrates synthetic lethality 14 March 2023 at 9:30am
Appendix 4D - Half Year Accounts - 31 December 2022 24 February 2023 at 6:40pm
Application for quotation of securities - PAB 16 February 2023 at 2:20pm
Change in substantial holding 15 February 2023 at 5:45pm
Change in substantial holding 3 February 2023 at 4:25pm
Change in substantial holding 3 February 2023 at 4:25pm
Appendix 4C - Quarterly - 31 December 2022 31 January 2023 at 9:45am
Patrys Receives R&D Tax Incentive Refund 30 January 2023 at 10:20am
Response to ASX Price Query 14 December 2022 at 3:40pm
Investor Webinar Presentation 24 November 2022 at 2:00pm
Final Director's Interest Notice 17 November 2022 at 9:55am
Initial Director's Interest Notice 17 November 2022 at 9:45am
Notification regarding unquoted securities - PAB 17 November 2022 at 9:45am
Results of Annual General Meeting 16 November 2022 at 3:59pm
Chairman's Address and CEO Presentation to 2022 AGM 16 November 2022 at 10:10am
Patrys Appoints Dr Charmaine Gittleson as Chairman 16 November 2022 at 9:15am
Appendix 4C - Quarterly - 30 September 2022 28 October 2022 at 9:50am
PAT DX3 Crosses Blood Brain Barrier in Healthy Animals 17 October 2022 at 9:10am
Notification of cessation of securities - PAB 14 October 2022 at 10:10am
Notice of Annual General Meeting/Proxy Form 13 October 2022 at 12:20pm
Final Director's Interest Notice 6 September 2022 at 9:45am
Investor presentation 1 September 2022 at 9:50am
Initial Director's Interest Notice 31 August 2022 at 10:00am
Appointment of Non-Executive Director 31 August 2022 at 9:59am
Appendix 4G and Corporate Governance Statement 30 August 2022 at 7:05pm
Appendix 4E and 2022 Annual Report 30 August 2022 at 7:05pm
PAT-DX1 From Engineering Run Meets all Specification Tests 30 August 2022 at 9:35am
New Research Grant For Deoxymabs in Metastatic Breast Cancer 26 August 2022 at 10:20am
PAT-DX1/Radiation Combination Improves Brain Cancer Survival 10 August 2022 at 10:00am
Retirement of Non-Executive Chair 8 August 2022 at 9:30am
Appendix 4C - Quarterly - 30 June 2022 28 July 2022 at 9:25am
Change in substantial holding 27 July 2022 at 12:25pm
PAT-DX1 Engineering Run Successfully Completed 4 July 2022 at 9:35am
New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis 14 June 2022 at 9:20am
CBCF funding to support deoxymab brain cancer development 3 June 2022 at 2:30pm
Patrys CEO to present at Bioshares Biotech Summit 11 May 2022 at 10:20am
Appendix 4C - Quarterly - 31 March 2022 28 April 2022 at 10:25am
Patrys strengthens executive team on path to clinic 26 April 2022 at 9:25am
Section 708A Cleansing Statement 14 April 2022 at 5:20pm
Application for quotation of securities - PAB 14 April 2022 at 5:20pm
Stable Cell Line for Production of PAT-DX3 Established 28 February 2022 at 9:10am
Appendix 4D - Half Year Accounts - 31 December 2021 24 February 2022 at 5:50pm
Application for quotation of securities - PAB 8 February 2022 at 10:55am
Appendix 4C - Quarterly - 31 December 2021 31 January 2022 at 10:10am
Register to track PAB and receive email alerts.